Industry Sectors - Biotechnology: First

Ravi Mehrotra & team Credit Suisse

The buy side says: “Ravi is an independent thinker who’s not afraid to challenge the status quo.”

Ravi Mehrotra, 38, leads Credit Suisse to a second consecutive first-place finish. The two-­member team downgraded Denmark’s Genmab to underperform in November 2009, at 114.50 Danish kroner, just a few weeks after the company, in a partnership with Glaxo­SmithKline, received accelerated approval of Arzerra from the U.S. Food and Drug Administration for use in the treatment of chronic lymphocytic leukemia; the analysts believed it would take a while for the product to gain sales traction. In early December 2010, after Genmab’s stock had plummeted 42.2 percent, to Dkr66.20, and lagged the sector by a whopping 31.5 percentage points, they upgraded it to neutral, on valuation. The stock had slipped an additional 1.1 percent by the end of that month, to Dkr65.50, putting it slightly ahead of the sector’s 1.4 percent decline.